Audit: QRS - Ubiquinol for Health & Longevity
Audit conducted on 12/08/2026 04:47 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated span traces to ER text: protocol cells to ER Therapeutic Protocol (ER 395, 401, 403), time cells to ER 443, benefit/risk tiers to the ER tier headings, gates to ER 344-373, markers to the ER biomarker table (ER 473-480), qualitative items to ER 484-489. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious wording carried over: marker_2_target keeps “No established target” (ER 474); marker_7_target keeps “commonly 2.0–3.0” (ER 479); marker_7_why keeps “disputed reduction in warfarin effect” (ER 479). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retain their full force (“unless oncologist-approved”, “within the past 12 months”); no benefit is upgraded beyond its ER tier. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gates draw only on ER Key Interactions & Contraindications, risks only on ER Potential Risks & Side Effects; no Benefit- or Risk-Modifying Factor appears in a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs, author names, or brand names anywhere in the QRS; only drug names that the ER itself lists (ER 346, 348, 350, 352). |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | The only attribution, “Leading practitioners’ general-health range” (action_1_sub), mirrors ER 395 “Leading practitioners use 100–200 mg/day”. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Same measured, evidence-weighted register as the ER, including the ER’s own hedge that benefit in healthy adults is unproven. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Concrete ranges, thresholds, and time horizons throughout; framing enables action without overselling. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Practice is reported (“Leading practitioners’ general-health range”), not prescribed. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Descriptive throughout; the footer disclaimer is template text and unchanged. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “should”, or “advised” appears in the populated spans. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns or imperatives anywhere in the populated spans. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to biomarker names, where they are unavoidable; elsewhere plain wording is used (“cholesterol-lowering drugs”, “blood levels”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier entries are noun phrases; marker “Why” cells are trimmed versions of the ER column. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no “you” or “your” in the document. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes plasma CoQ10 testing, ApoB, hs-CRP, and home blood-pressure tracking — a proactive, self-optimizing reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Meal-timed dosing, dose splitting, and an eight-marker monitoring panel assume that willingness. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Optimal functional ranges rather than conventional cut-offs are used throughout the Monitoring table. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance separates the responsive groups (statin users, over-fifties with low levels, cardiometabolic disease) from healthy adults, where it states benefit is unproven. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Clinical register throughout (“hypersensitivity”, “antihypertensives”, “light-headedness on standing”); the plainer At-A-Glance wording is required by item 7.4 and taken from ER 511-513. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings match the template byte-for-byte (QRS 446, 490, 534, 569, 580, 611, 639, 643-645, 773 and the four tier labels in both tier cards). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Every template span name is present; the template’s marker_#_* and qualitative_item_# placeholders are expanded to marker_1..8 and qualitative_item_1..6 as intended. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against the template shows changes only inside checklist-governed spans, the metadata block, and the title; the website="evidence_review", website="audit", and website="full_review" spans and all CSS are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section mapped into the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1_label “Standard maintenance dose”, action_2_label “Best time of day”, action_3_label “Half-life and dose splitting” are the ER bold labels verbatim (ER 395, 401, 403); marker names are the ER table row labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels are drawn from the wording of ER 443 (“Plasma levels plateau”, “Fatigue and blood-pressure changes”, “cardiac outcome differences”); no label is invented. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Scan for emoji code points returns none; the ER’s 🟩/🟥/🟨 and ⚠️ markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Each section is condensed to its budget: benefit and risk tiers are semicolon-joined noun phrases, gate items are stripped to the key fact, marker “Why” cells are shortened from the ER column, and At-A-Glance sits at 59 words. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Single comment at QRS 2-14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13; the descriptive text on line 2 precedes the block. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; none of its values are repeated in the header or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration: "00:03" is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: ubiquinol_2026-0812-0106_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0812-0421, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the actual filename ubiquinol_2026-0812-0106_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | QRS 22: “Ubiquinol for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | QRS 417: “Ubiquinol for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | QRS 421: “08/12/2026”, the correct reformatting of 2026-0812-0421. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | QRS 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header holds only the title and the template subline; the ER’s “Also known as” line was correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses the ER Conclusion’s two-fact-plus-gap structure and names the groups for whom the case holds (ER 511-513). |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words, verified by word count. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Absorption advantage, the ubiquinone outcome record, the price premium, the responsive groups, and the unproven healthy-adult case each map to a separate passage in ER 511-513. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “cholesterol-lowering drugs”, “heart or metabolic disease”, “the older form of coenzyme Q10”; no acronyms or classification terms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect estimate or statistic appears. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All four items come from the “Populations who should avoid Ubiquinol” list at ER 368-373. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All four ER avoid-populations are present, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | QRS 572-575: four discrete <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | ER’s explanatory tails are stripped, e.g. “where supplementation data are insufficient rather than negative” (ER 371) does not appear; no dashed clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “within the past 12 months”, “(unless oncologist-approved)”, and “(soy-derived, polysorbate)” are all retained from ER 370-373. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER does name such populations, and the section is correspondingly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eleven items map to ER bullets 344-366. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Eleven of the ER’s twelve interaction bullets are carried; the pro-oxidant chemotherapy bullet is correctly omitted here because it appears as a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | QRS 583-601: eleven discrete <li> elements. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | All ER mechanism and safeguard tails after the em-dash are stripped, e.g. “Caution — additive glucose lowering risks hypoglycaemia” (ER 348) is reduced to the agent names alone. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER parenthetical survives in trimmed form: statin, sulfonylurea, P-gp, and BP-supplement example lists are kept; the antihypertensive parenthetical retains all three drug classes. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names twelve such interactions, and the section is correspondingly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells come from ER Therapeutic Protocol bullets at ER 395, 401, and 403. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing, and splitting/frequency are the three executable decisions; the remaining ER bullets are modifiers rather than actions. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides more than three actionable aspects, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry ER-derived content, including the 100–200 mg/day window and the flattening of systolic benefit above it (ER 395). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Cardiac outcomes, plasma repletion, and fatigue/blood pressure are exactly the three horizons the ER gives at line 443. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Cardiac events and plasma repletion are both High-tier benefits and lead; fatigue and blood pressure are Medium-tier and come last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are present in the ER, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “2 years”, “~4 weeks”, and “8–12 weeks” with subs all trace to ER 443. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (ER 443). |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All sixteen entries correspond to ER benefit headings at ER 148-246. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present and populated with the matching tier’s items. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Entries are the ER headings reduced to noun phrases; the ER’s magnitude lines, mechanisms, and ⚠️ Conflicted markers are all dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear anywhere in the four benefit spans. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All ten entries correspond to ER risk headings at ER 266-328. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present and populated with the matching tier’s items. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Entries are ER headings reduced to noun phrases; the magnitude paragraphs and the ⚠️ Conflicted marker on the warfarin item are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear anywhere in the four risk spans. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows and cadence come from ER Monitoring Protocol & Defining Success (ER 467-480). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarker table rows are present, with names verbatim and targets preserved (including “Below 125 pg/mL” for NT-proBNP). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | QRS 764-766 reproduces every interval from ER 469: 8 weeks, 3 months then 6–12 months, daily then weekly, and INR at 1, 2 and 4 weeks. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the qualitative-marker list at ER 484-489. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are present, in ER order, with none added. |
Issues 12/08/2026 04:47
Pass rate 100.00%. No issues found.
Issues 12/08/2026 04:42
- 1.1 — Time-to-effect subline overgeneralized: [time_3_sub] (line 523) says “Effects were stronger beyond 12 weeks” under the label “Fatigue and blood pressure”, while ER line 443 limits that finding to blood pressure only.
- 7.3 — At-A-Glance age threshold widened: “past fifty with low levels” (line 436) does not match ER line 513, which reads “past their fifties with low measured levels”.
- 1.3 — Qualitative marker made assertive: [qualitative_item_5] (line 792) says gastrointestinal comfort “signals a need to split”, strengthening the ER’s conditional “signals whether the dose needs splitting” (ER line 488).
Fixes 12/08/2026 04:42
- 1.1 — Time-to-effect subline scoped to blood pressure: Changed [time_3_sub] from “Effects were stronger beyond 12 weeks.” to “Blood-pressure effects were stronger beyond 12 weeks.”, matching the ER’s blood-pressure-only finding.
- 7.3 — At-A-Glance age threshold restored: Changed “past fifty with low levels” to “past their fifties with low measured levels”, matching the ER Conclusion wording; At-A-Glance is now 59 words.
- 1.3 — Qualitative marker made conditional again: Changed [qualitative_item_5] from “which signals a need to split” to “which signals whether the dose needs splitting”, restoring the ER’s conditional phrasing.
Issues 12/08/2026 04:36
- 9.4 — Trailing clauses on interaction items: Three [caution_items] carry an explanatory clause lifted from the ER bullet body rather than the bold label — “Statins, no adverse interaction (…)” (line 596), “Selenium, potentiating rather than adverse” (line 597), and “Vitamin E (alpha-tocopherol), mutually reinforcing” (line 598).
- 2.5 — Imperative in protocol cell: [action_3_value] reads “Split totals above 100 mg” (line 478), an instruction to the reader, where the ER states the same fact descriptively (“Splitting doses above 100 mg is done for tolerability and absorption saturation”, ER line 403).
Fixes 12/08/2026 04:36
- 9.4 — Trailing clauses on interaction items: Stripped the explanatory clauses from three [caution_items] — “Statins, no adverse interaction (atorvastatin, simvastatin, rosuvastatin)” to “Statins (atorvastatin, simvastatin, rosuvastatin)”, “Selenium, potentiating rather than adverse” to “Selenium”, and “Vitamin E (alpha-tocopherol), mutually reinforcing” to “Vitamin E (alpha-tocopherol)”.
- 2.5 — Imperative in protocol cell: Changed [action_3_value] from the imperative “Split totals above 100 mg” to the descriptive “Splitting above 100 mg”, matching the ER’s non-instructional phrasing.
Issues 12/08/2026 04:23
- 4.5 — Content exceeds one A4 page: The sheet carries eleven full-length [caution_items] (lines 591–611), an eight-row Monitoring table with near-verbatim ER
TargetandWhyprose (lines 657–772), a 220-character [monitoring_cadence] (lines 776–780) and three-line Protocol/Time subs, giving an estimated rendered height of roughly twice the one-page budget. - 1.4 — Monitoring fact placed under Time to effect: [time_2_sub] (QRS line 517) ends with “rechecked at 8 weeks to settle the dose”, a monitoring-cadence fact from the ER
Monitoring Protocol & Defining Successsection (ER line 469), which also duplicates [monitoring_cadence].
Fixes 12/08/2026 04:23
- 1.4 — Monitoring cadence removed from Time to effect: [time_2_sub] changed from “Plasma levels plateau in about four weeks; rechecked at 8 weeks to settle the dose.” to “Plasma levels plateau in about four weeks.”, leaving the 8-week recheck solely in [monitoring_cadence] where the ER places it.
- 4.5 — Monitoring table condensed: Shortened all eight
Whycells plus [marker_2_target] and [marker_7_target] (e.g. “Tracks cardiac strain where heart failure is the reason for supplementing” → “Tracks cardiac strain in heart failure”), keeping all eight ER biomarkers. - 4.5 — Protocol and Time-to-effect subs trimmed: Removed the mechanistic tails from the three [action_#sub] and the three [time#_sub] cells, dropping clauses such as “absorption depends on bile flow” and “and absorption saturation”.
- 4.5 — Decision-gate items shortened: Trimmed three [stop_items] and the additive-blood-pressure [caution_items] entry (e.g. “Documented hypersensitivity to any softgel component (soy-derived or polysorbate excipients)” → “Hypersensitivity to softgel components (soy-derived, polysorbate)”), while retaining all four contraindications and all eleven interactions.
- 4.5 — Qualitative items and cadence condensed: Trimmed the explanatory tails from four [qualitative_item_#] entries and tightened [monitoring_cadence], without dropping any marker or cadence step.